Search research articles
Contact Us
Filters
Showing results (1-10 of 35) with videos related to
Page
of 4
Sort By:
Breast Cancer Research : BCR
|
December 19, 2003
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
Wenlin Shao, Myles Brown
Molecular and Cellular Biology
|
April 25, 2002
ERAP140, a conserved tissue-specific nuclear receptor coactivator
Wenlin Shao, Shlomit Halachmi, Myles Brown
EMBO Reports
|
February 15, 2015
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini, Wenlin Shao, William R Sellers
Proceedings of the National Academy of Sciences of the United States of America
|
August 4, 2004
Coactivator AIB1 links estrogen receptor transcriptional activity and stability
Wenlin Shao, Erika Krasnickas Keeton, Donald P McDonnell, et al.
BMC Cell Biology
|
March 30, 2007
The OXR domain defines a conserved family of eukaryotic oxidation resistance proteins
Mathieu Durand, Adrianne Kolpak, Timothy Farrell, et al.
International Journal of Cancer
|
February 4, 2010
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance
Wenlin Shao, Joseph D Growney, Yun Feng, et al.
Journal of Medicinal Chemistry
|
July 25, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases
Michael D Shultz, Dyuti Majumdar, Donovan N Chin, et al.
Genes, Chromosomes & Cancer
|
September 28, 2002
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones
Marie-Joëlle Mozziconacci, Angelika Rosenauer, Audrey Restouin, et al.
Frontiers in Immunology
|
March 19, 2021
Evaluation of Combination Strategies for the A<sub>2A</sub>R Inhibitor AZD4635 Across Tumor Microenvironment Conditions <i>via</i> a Systems Pharmacology Model
Veronika Voronova, Kirill Peskov, Yuri Kosinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 35) with videos related to
Sort By:
Page
of 4
Breast Cancer Research : BCR
|
December 19, 2003
Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy
Wenlin Shao, Myles Brown
Molecular and Cellular Biology
|
April 25, 2002
ERAP140, a conserved tissue-specific nuclear receptor coactivator
Wenlin Shao, Shlomit Halachmi, Myles Brown
EMBO Reports
|
February 15, 2015
Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure
Raymond Pagliarini, Wenlin Shao, William R Sellers
Proceedings of the National Academy of Sciences of the United States of America
|
August 4, 2004
Coactivator AIB1 links estrogen receptor transcriptional activity and stability
Wenlin Shao, Erika Krasnickas Keeton, Donald P McDonnell, et al.
BMC Cell Biology
|
March 30, 2007
The OXR domain defines a conserved family of eukaryotic oxidation resistance proteins
Mathieu Durand, Adrianne Kolpak, Timothy Farrell, et al.
International Journal of Cancer
|
February 4, 2010
Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance
Wenlin Shao, Joseph D Growney, Yun Feng, et al.
Journal of Medicinal Chemistry
|
July 25, 2013
Structure-efficiency relationship of [1,2,4]triazol-3-ylamines as novel nicotinamide isosteres that inhibit tankyrases
Michael D Shultz, Dyuti Majumdar, Donovan N Chin, et al.
Genes, Chromosomes & Cancer
|
September 28, 2002
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones
Marie-Joëlle Mozziconacci, Angelika Rosenauer, Audrey Restouin, et al.
Frontiers in Immunology
|
March 19, 2021
Evaluation of Combination Strategies for the A<sub>2A</sub>R Inhibitor AZD4635 Across Tumor Microenvironment Conditions <i>via</i> a Systems Pharmacology Model
Veronika Voronova, Kirill Peskov, Yuri Kosinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2020
The Pharmacokinetic-Pharmacodynamic (PKPD) Relationships of AZD3229, a Novel and Selective Inhibitor of KIT, in a Range of Mouse Xenograft Models of GIST
Venkatesh Pilla Reddy, Rana Anjum, Michael Grondine, et al.
Page
of 4